|
Secondary Myelodysplastic Syndrome and Leukemia in Acquired Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria |
May 2020 |
Blood |
Aplastic Anemia, Myelodysplastic Syndromes (MDS), Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
Genetics of Progression From MDS to Secondary Leukemia |
May 2020 |
Blood |
Myelodysplastic Syndromes (MDS) |
|
Cyclosporine Enhances the Sensitivity to Lenalidomide in MDS/AML in Vitro |
May 2020 |
Experimental Hematology |
Myelodysplastic Syndromes (MDS) |
|
Establishing Specific Response Criteria for MDS/MPN - Getting Closer to Reality? |
May 2020 |
Best practice & research. Clinical haematology |
Myelodysplastic Syndromes (MDS) |
|
SF3B1-mutant myelodysplastic syndrome as a distinct disease subtype - A Proposal of the International Working Group for the Prognosis of Myelodysplastic Syndromes (IWG-PM) |
Apr 2020 |
Blood |
Myelodysplastic Syndromes (MDS) |
|
Rewriting the rules for care of MDS and AML patients in the time of COVID-19 |
Apr 2020 |
Leukemia Research Reports |
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) |
|
Alcohol use is not a significant contributor to myelodysplastic syndromes |
Apr 2020 |
Cancer Causes & Control : CCC |
Myelodysplastic Syndromes (MDS) |
|
Targeting TP53 Mutations in Myelodysplastic Syndromes |
Apr 2020 |
Hematology/oncology clinics of North America |
Myelodysplastic Syndromes (MDS) |
|
Evolving therapies for lower-risk myelodysplastic syndromes |
Apr 2020 |
Annals of Hematology |
Myelodysplastic Syndromes (MDS) |
|
Hypomethylating Agent Therapy in Myelodysplastic Syndromes With Chromosome 3 Abnormalities |
Mar 2020 |
Clinical Lymphoma , Myeloma & Leukemia |
Myelodysplastic Syndromes (MDS) |
